PANTHERx Specialty Pharmacy, The Rare Disease Specialty Pharmacy®, unveiled a new, sophisticated and modern brand identity recently while simultaneously announcing a new, state-of-the-art third location.
PANTHERx’s third location, near the Pittsburgh International Airport, will add nearly 50,000 square feet of state-of-the-art operational capacity to PANTHERx’s operations. The third site will join current facilities in Pittsburgh and Canfield, Ohio. This new location will give PANTHERx the ability to stay ahead of operational needs and fulfill its mission to transform lives by delivering medical breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions.
PANTHERx is successfully implementing its strategy of securing biopharma contracts. Recent activities include:
PANTHERx® announced the expansion of its oncology franchise to include Precision Medicine. PANTHERx’s focus on rare and devastating diseases now extends to the full complement of oncology medications including cell and gene therapy. PANTHERx has recently secured access to multiple limited/exclusive distribution oral oncology products that use a personalized gene-based approach to treatment.
PANTHERx announced a collaboration with Cardinal Health which has been delivering services for cell and gene therapies over the past few years using a “buy and bill” model, but identified an opportunity to augment its offering with specialty pharmacy services for manufacturers who require a different reimbursement approach.
PANTHERx and RxCrossroads™ by McKesson, the leading commercial solutions partner for life sciences companies, announced their collaborative program to simplify the channel for precision medicine therapies. Recognizing a significant unmet need for cell and gene therapy programs, as well as a deep pipeline of products that are set to launch over the next several years, PANTHERx® and RxCrossroads™ by McKesson are simplifying processes, coalescing strengths, gaining efficiencies, and creating a best-in-class portfolio for biopharma, provider, and payer partners.